XENE EBITDA Growth
Xenon Pharmaceuticals Inc · EBITDA Growth
XENE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-31.92%period ending
XENE TTM EBITDA YoY % (985.16% → -31.92%)
Year-over-year change
High-resolution chart · PNG
XENE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -31.9174% | |
| -37.4243% | |
| -29.8578% | |
| -31.4001% | |
| -34.9935% | |
| -31.8203% | |
| -31.4589% | |
| -28.5564% | |
| -29.5399% | |
| -41.8038% | |
| -70.2753% | |
| -79.9169% | |
| -107.6384% | |
| -96.088% | |
| -58.3247% | |
| -64.9623% | |
| -45.4518% | |
| -112.0142% | |
| -173.4905% | |
| -147.6354% | |
| -127.478% | |
| -3.9651% | |
| 28.1801% | |
| 27.5036% | |
| 37.563% | |
| 10.013% | |
| -22.2591% | |
| -14.0169% | |
| -59.4813% | |
| -49.8724% | |
| -4.8124% | |
| -13.883% | |
| 5.8309% | |
| -0.9432% | |
| -29.5203% | |
| -35.4691% | |
| -94.8921% | |
| -239.7992% | |
| -187.7929% | |
| -263.9139% | |
| -494.9973% | |
| -265.0521% | |
| -170.2719% | |
| -141.7772% | |
| -68.7215% | |
| -56.6215% | |
| 13.6988% | |
| 103.0762% | |
| 985.1598% |